To evaluate the superiority of cognitive behavioral therapy using the Aurora® digital medical device + conventional drug treatment, compared to conventional drug treatment alone, in reducing anxiety symptoms, as assessed by the change in the GAD-7 scale at 12 weeks of treatment, relative to baseline.
Men and women aged ≥18 and ≤65 years.
Diagnosis of generalized anxiety disorder (GAD) based on DSM-5-TR criteria.
Score ≥10 on the GAD-7 (Generalized Anxiety Disorder Scale) instrument
That they agree to participate in the study by signing the informed consent form.
Concomitant alcohol use disorder or recreational drug use disorder.
Consumption of energy drinks.
Excessive caffeine consumption (more than 150 mg per day).
Patients with hypersensitivity to escitalopram (Selective®) or duloxetine (Arquera®) and/or any component of the formulation.